In September, there were many blockbuster events in the pharmaceutical industry, including new listings, buying technology, setting up subsidiaries, business spin-offs or mergers and acquisitions.
.
.
From all points of view, the changes in the pharmaceutical industry behind are accelerating, and pharmaceutical companies are laying
out from many aspects in order to enhance their competitiveness.
【Buy technology】
On September 2, Yunnan Baiyao announced that the company signed the "Technology Transfer and Cooperative Development Agreement" with Peking University Hospital and Beishi Research Institute, and intends to obtain 20 million yuan of prostate-specific membrane antigen (PSMA) targeted nuclear drugs related patents developed by the latter, and the company will conduct research and development, production and commercialization activities
on the cooperative targets around the world.
The parties intend to continue to jointly develop the project on the basis of the current research and development, and eventually realize the registration and commercialization
of related drugs.
Yunnan Baiyao said that after the completion of the transfer and introduction of the cooperation target, the company's Academia Sinica will start relevant research work in accordance with the requirements of the new drug clinical trial application (IND) declaration, and the development of the project will help the company accelerate the pace
of entering the field of nuclear drugs.
【Establishment of a subsidiary】
On September 21, Northeast Pharmaceutical issued an announcement that it intends to invest 500 million yuan in its own funds to establish a wholly-owned subsidiary, "Northeast Pharmaceutical Group (Shanghai) Biotechnology Co.
, Ltd.
(tentative), and the company holds 100% of its equity
.
For the establishment of a wholly-owned subsidiary with its own funds investment, the company said that it can accelerate the implementation of ADC drugs and CAR-T cell therapy technology cooperation projects introduced by agreement with MedAbome, Inc.
in the
United States.
It is reported that the subsidiary initially focused on promoting the research and development of cooperative projects to meet the preparation of clinical products and build a small production platform
for culture media.
【Business Spin-off】
In September, multinational pharmaceutical company Novartis said it planned to close its Sandoz generic drug plant in Wilson, North Carolina, around the end of 2023, citing the inability to make full use of the U.
S.
plant
.
The plant employs approximately 246 people and specializes in the production of oral solid preparation products
sold primarily in the U.
S.
and Canadian markets.
This move is considered by the industry to be a new move for Novartis to shift its strategic focus and carry out a split plan, and it is expected that after this spin-off, Novartis will focus more on high-value business, especially in the direction of
innovative drugs.
【Expansion】
On September 21, Qianhong Pharmaceutical announced that the company signed the "Changzhou Qianhong Pharmaceutical API Production Base Project Contract"
with the People's Government of Zhongxiang City, Hubei Province on September 20.
The company intends to use its own funds to invest 600 million yuan in a new API production base project
in Zhongxiang City, Hubei Province.
The production base is divided into two phases of construction, after the project reaches production, it will form an annual production capacity
of 6.
5 tons of high-end antithrombotic drugs, 125 tons of crude pancreatic enzymes, 75 billion pharmaceutical proteases, 5 tons of targeted anti-tumor APIs, and 100 million pharmaceutical packaging materials.
Qianhong Pharmaceutical said that after the new construction of the project, it will further expand the company's new drug and core product industry chain and enhance the company's core competitiveness
.
【M&A】
In September, more than 10 A-share listed companies issued announcements related to mergers and acquisitions
.
For example, Da Ren Tang intends to acquire no more than 11.
9686 million shares of the existing shareholders (excluding Tianjin Pharmaceutical Group Co.
, Ltd.
) of Tianjin Zhongxin Keju Biopharmaceutical Co.
, Ltd.
("Keju Biologics") in stages at a price of not more than 9 yuan per share by way of agreement transfer, with a total investment of not more than 108 million yuan
.
Hygia Medical intends to acquire a 30% stake in Kaiyuan Xiehua Hospital Co.
, Ltd.
for a cash consideration of RMB15.
3 million
.
Upon completion, the Company will indirectly hold a 70% stake in the Target Hospital through Gamma Star Technology and control the remaining 30% equity interest
in the Target Hospital to be held by the Buyer under the new contractual arrangement.
As a result, the target hospital will become a wholly-owned subsidiary of the Company and the financial results of the target hospital will continue to be consolidated into the Group's financial statements
.
In addition, Huadong Pharmaceutical intends to acquire 60% of the equity of Huaren Technology, China Resources Shuanghe intends to acquire 50.
11% of the equity of Shenzhou Biotechnology, and Longshen Rongfa intends to acquire 70% of the equity of Puan Pharmaceutical for 326 million yuan
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
